Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Lux, Michael P., Nabieva, Naiba, Hartkopf, Andreas D., Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Wimberger, Pauline, Hielscher, Carsten, Geberth, Matthias, Abenhardt, Wolfgang, Kurbacher, Christian, Wuerstlein, Rachel, Thomssen, Christoph, Untch, Michael, Fasching, Peter A., Janni, Wolfgang, Fehm, Tanja N., Wallwiener, Diethelm, Schneeweiss, Andreas, Brucker, Sara Y.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357172/
https://ncbi.nlm.nih.gov/pubmed/30577662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11010010
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak